These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 38203475)
21. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708 [TBL] [Abstract][Full Text] [Related]
22. [Blastic plasmacytoid dendritic cell tumor treated with DVT regimen: a case report and literature review]. Shi J; Xu N; Niu Y; Jia SX; Yang CM; Fang MY Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):86-89. PubMed ID: 38527844 [TBL] [Abstract][Full Text] [Related]
23. Cytologic features of blastic plasmacytoid dendritic cell neoplasm involving liver: A case report and literature review. Ding Y; Yang J; Lindsey K Diagn Cytopathol; 2021 Feb; 49(2):E80-E83. PubMed ID: 32852895 [TBL] [Abstract][Full Text] [Related]
24. Mutated ZRSR2 and CUL3 accelerate clonal evolution and confer venetoclax resistance via RAS signaling pathway in blastic plasmacytoid dendritic cell neoplasm. Fukuchi K; Koyama D; Takada M; Mori H; Hayashi K; Asano N; Sato Y; Fukatsu M; Takano M; Takahashi H; Shirado-Harada K; Kimura S; Yamamoto T; Ikezoe T Int J Hematol; 2023 Oct; 118(4):489-493. PubMed ID: 37029861 [TBL] [Abstract][Full Text] [Related]
26. Relapse of tagraxofusp treated blastic plasmacytoid dendritic cell neoplasm with loss of CD123 expression. Gulati R; Abu-Salah A; Salous T; Nassiri M J Hematop; 2022 Mar; 15(1):35-39. PubMed ID: 38358597 [TBL] [Abstract][Full Text] [Related]
27. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023. Pemmaraju N; Kantarjian H Clin Adv Hematol Oncol; 2023 May; 21(5):257-264. PubMed ID: 37145496 [TBL] [Abstract][Full Text] [Related]
28. Profiling endogenous, environmental, and infectious disease mutational signatures in blastic plasmacytoid dendritic cell neoplasms. Small C; Mukerjee S; Jangam D; Gollapudi S; Singh K; Jaye DL; Aung PP; Querfeld C; Yao K; Chisholm KM; Pullarkat S; Wang S; Gru A; Hussaini M; George TI; Ohgami RS Int J Lab Hematol; 2023 Oct; 45(5):726-734. PubMed ID: 37282364 [TBL] [Abstract][Full Text] [Related]
29. Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting. Dhakal P; Sy M; Sutamtewagul G; Mou E; Yu N; Pemmaraju N J Immunother Precis Oncol; 2024 Aug; 7(3):205-209. PubMed ID: 39219995 [TBL] [Abstract][Full Text] [Related]
30. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. Luskin MR; Lane AA Haematologica; 2024 Jan; 109(1):44-52. PubMed ID: 36951152 [TBL] [Abstract][Full Text] [Related]
31. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm. Zhang X; Sun J; Yang M; Wang L; Jin J Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682 [TBL] [Abstract][Full Text] [Related]
32. Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report. Sibai J; Chen R; Nabhani IA; Perusini MA; Sibai H EJHaem; 2022 Nov; 3(4):1374-1376. PubMed ID: 36467820 [TBL] [Abstract][Full Text] [Related]
33. Early T-cell precursor lymphoblastic leukemia accompanied by prominent blastic plasmacytoid dendritic cell proliferation mimicking blastic plasmacytoid dendritic cell neoplasm: an exceptional case report and literature review. Liao H; Yu J; Liu Y; Zhao S; Zhu H; Xu D; Jiang N; Zheng Q J Cancer Res Clin Oncol; 2022 Oct; 148(10):2911-2919. PubMed ID: 35933443 [TBL] [Abstract][Full Text] [Related]
34. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a rare entity. Lim MS; Lemmert K; Enjeti A BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26791132 [TBL] [Abstract][Full Text] [Related]
35. Targeting CD123 in BPDCN: an emerging field. DiPippo AJ; Wilson NR; Pemmaraju N Expert Rev Hematol; 2021 Nov; 14(11):993-1004. PubMed ID: 34607517 [TBL] [Abstract][Full Text] [Related]
36. Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm. Kharfan-Dabaja MA; Cherry M Hematol Oncol Clin North Am; 2020 Jun; 34(3):621-629. PubMed ID: 32336425 [TBL] [Abstract][Full Text] [Related]
37. Blastic plasmacytoid dendritic cell neoplasm and cerebral toxoplasmosis: a case report. Florescu AM; Sørensen ALT; Nielsen HV; Tolnai D; Sjö LD; Larsen KL; Al-Karagholi MA BMC Neurol; 2022 Jun; 22(1):233. PubMed ID: 35751052 [TBL] [Abstract][Full Text] [Related]
38. Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA Mutations and Epigenetics. Sapienza MR; Pileri S Hematol Oncol Clin North Am; 2020 Jun; 34(3):511-521. PubMed ID: 32336416 [TBL] [Abstract][Full Text] [Related]
39. Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A review. Wang Y; Xiao L; Yin L; Zhou L; Deng Y; Deng H Medicine (Baltimore); 2023 Feb; 102(7):e32904. PubMed ID: 36800625 [TBL] [Abstract][Full Text] [Related]